Clinical trials
Neurologic Manifestations trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 5 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 4 |
| National Taiwan University Hospital | 3 |
| Shanghai University of Traditional Chinese Medicine | 2 |
| University of Chile | 2 |
| Ain Shams University | 1 |
| Arnold, George, M.D. | 1 |
| Assaf-Harofeh Medical Center | 1 |
| Bariatric Medicine Institute, Salt Lake City, UT | 1 |
| BioDirection Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neurologic Manifestations | 60 |
| Mental Disorders | 9 |
| Rare Diseases | 9 |
| Stroke | 8 |
| Nervous System Diseases | 7 |
| Pain | 4 |
| Brain Injuries | 3 |
| COVID-19 | 3 |
| Central Nervous System Diseases | 3 |
| Multiple Sclerosis | 3 |
Trials
Showing 51 to 60 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.